KevinMD November 29, 2025
Holli Bradish-Lane

I’ve seen clients start GLP-1 medications full of hope, and stop them feeling betrayed by their own biology. Some reached their limit with side effects: relentless nausea, fatigue, or the quiet loss of joy in eating. Others simply couldn’t afford to stay on. A few never saw the promised results at all. But for nearly all of them, the story ended the same way: one step forward, five steps back.

We celebrate the success stories of GLP-1s, but we rarely talk about the crash that follows when treatment stops. And it’s not just psychological. The body rebounds fast: hunger, weight, and metabolic chaos rush back in.

The problem isn’t the medication itself. It’s that we’ve built an elegant on-ramp for...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
What’s new with GLP-1s
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable

Share Article